Literature DB >> 26828905

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

J A Yared1, N Hardy1, Z Singh2, S Hajj3, A Z Badros1, M Kocoglu1, S Yanovich1, E A Sausville1, C Ujjani4, K Ruehle1, C Goecke1, M Landau1, A P Rapoport1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26828905     DOI： 10.1038/bmt.2015.346

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

1.  Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

Authors:  Michael R Green; Scott Rodig; Przemyslaw Juszczynski; Jing Ouyang; Papiya Sinha; Evan O'Donnell; Donna Neuberg; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

2.  Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

Authors:  James Larkin; Christopher D Lao; Walter J Urba; David F McDermott; Christine Horak; Joel Jiang; Jedd D Wolchok
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

3.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

4.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors:  Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

5.  Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.

Authors:  David J Andorsky; Reiko E Yamada; Jonathan Said; Geraldine S Pinkus; David J Betting; John M Timmerman
Journal:  Clin Cancer Res       Date:  2011-05-03       Impact factor: 12.531

6.  B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

Authors:  Ryan A Wilcox; Andrew L Feldman; David A Wada; Zhi-Zhang Yang; Nneka I Comfere; Haidong Dong; Eugene D Kwon; Anne J Novak; Svetomir N Markovic; Mark R Pittelkow; Thomas E Witzig; Stephen M Ansell
Journal:  Blood       Date:  2009-07-13       Impact factor: 22.113

7.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

Review 8.  Graft-versus-leukemia effects of transplantation and donor lymphocytes.

Authors:  Hans-Jochem Kolb
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113
  8 in total
  24 in total

1.  Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection.

Authors:  Mitra Bhattacharyya; Pablo Penaloza-MacMaster
Journal:  AIDS Res Hum Retroviruses       Date:  2018-04-18       Impact factor: 2.205

Review 2.  Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.

Authors:  Reid W Merryman; Philippe Armand
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 3.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

4.  PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.

Authors:  J C Albring; S Inselmann; T Sauer; C Schliemann; B Altvater; S Kailayangiri; C Rössig; W Hartmann; J R Knorrenschild; K Sohlbach; C Groth; M Lohoff; A Neubauer; W E Berdel; A Burchert; M Stelljes
Journal:  Bone Marrow Transplant       Date:  2016-11-28       Impact factor: 5.483

Review 5.  Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.

Authors:  Awais Ijaz; Ali Younas Khan; Saad Ullah Malik; Warda Faridi; Muhammad Asad Fraz; Muhammad Usman; Muhammad Junaid Tariq; Seren Durer; Ceren Durer; Atlantis Russ; Nadia Nunes Cavalcante Parr; Zeeshan Baig; Fnu Sagar; Zeeshan Ali; Ali McBride; Faiz Anwer
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-06       Impact factor: 5.742

6.  Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Authors:  Makoto Onizuka; Minoru Kojima; Keiko Matsui; Shinichiro Machida; Masako Toyosaki; Yasuyuki Aoyama; Hidetsugu Kawai; Jun Amaki; Ryujiro Hara; Akifumi Ichiki; Yoshiaki Ogawa; Hiroshi Kawada; Naoya Nakamura; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2017-01-17       Impact factor: 2.490

7.  Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group.

Authors:  C Baues; R Semrau; U S Gaipl; P J Bröckelmann; J Rosenbrock; A Engert; S Marnitz
Journal:  Strahlenther Onkol       Date:  2016-10-04       Impact factor: 3.621

8.  PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Authors:  Bradley M Haverkos; Diana Abbott; Mehdi Hamadani; Philippe Armand; Mary E Flowers; Reid Merryman; Manali Kamdar; Abraham Sebastian Kanate; Ayman Saad; Amitkumar Mehta; Siddhartha Ganguly; Timothy S Fenske; Parameswaran Hari; Robert Lowsky; Leslie Andritsos; Madan Jagasia; Asad Bashey; Stacey Brown; Veronika Bachanova; Deborah Stephens; Shin Mineishi; Ryotaro Nakamura; Yi-Bin Chen; Bruce R Blazar; Jonathan Gutman; Steven M Devine
Journal:  Blood       Date:  2017-05-03       Impact factor: 22.113

9.  PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Harriet M Kluger; Christopher R Zito; Gabriela Turcu; Marina K Baine; Hongyi Zhang; Adebowale Adeniran; Mario Sznol; David L Rimm; Yuval Kluger; Lieping Chen; Justine V Cohen; Lucia B Jilaveanu
Journal:  Clin Cancer Res       Date:  2017-02-21       Impact factor: 12.531

Review 10.  Pembrolizumab in classical Hodgkin's lymphoma.

Authors:  Joseph Maly; Lapo Alinari
Journal:  Eur J Haematol       Date:  2016-05-30       Impact factor: 2.997
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.